NasdaqGM:SMMTBiotechs
Does Summit Therapeutics (SMMT) Expanding Ivonescimab Trials Clarify Its Single-Asset Oncology Strategy?
Summit Therapeutics Inc. recently presented data for its investigational bispecific antibody ivonescimab at the 2026 European Lung Cancer Congress in Copenhagen, highlighting progress in multiple Phase III trials across non-small cell lung cancer and colorectal cancer.
The company now has 15 announced, ongoing, or completed Phase III studies for ivonescimab, including four Summit-sponsored global trials and ten China-based trials run by partner Akeso Inc., underscoring how extensively this...